Locate Bio
Locate is based in MediCity and has developed a family of unique, thermally-activated, injectable scaffolds that solidify within the body and can be used to support tissue growth before degrading away.

Profile
The TAOSTM (Targeted, Orchestrated Signalling) technology is a world first in tissue repair and enables the precision focus of therapeutic signals from small molecule or biological actives at the site of repair. TAOSTM has many potential application sites across the body.
Pipeline technology includes RPMax, a thermo-reversible matrix, and IntraStem, a new delivery system for cells; technologies that can meet industry recognised needs to advance cell therapy markets such as transfection, genome editing and induced pluripotent stem cells.
News and press releases
Locate Bio appoints Keith Valentine as the Non-Executive Chair of the Board of Directors
- 7th January 2021 3:31 pm·
New spin-out company signals quantum leap for brain imaging
- 8th December 2020 12:54 pm·
UK wide study aims to relieve millions who suffer from dry eye syndrome
- 7th October 2020 4:29 pm·
Eye-sight saving tech designed by Nottingham healthcare experts could help cut post-Covid NHS waiting lists
- 1st September 2020 11:44 am·
EventMAP software implementation helps NHS Foundation Trust staff return to work
- 30th July 2020 10:39 am·
Promethean Particles Wins Prestigious Institute of Physics Award
- 27th July 2020 11:36 am·
Locate Bio raises £2.25m for new spinal treatments
- 22nd July 2020 4:37 pm·
SurePulse lands £1m investment to expand its share of neonatal healthtech market
- 16th July 2020 5:05 pm·
University of Nottingham generates £1.5m from the sale of Oncimmune shares
- 15th June 2020 4:50 pm·
Scancell to initiate development of novel DNA vaccine against COVID-19
- 20th May 2020 3:35 pm·
Locate Bio announces the appointment of John von Benecke as CEO
- 18th May 2020 11:50 am·

@locatebio on Twitter
@Locate Bio is attending @Phacilitate's Advanced Therapies Week conference in Miami this week, after being named as one of their Top 20 companies to watch. #CellTherapy #GeneTherapy
@LocateBio senior management will be available for investor and partnering meetings at the #biotechshowcase in San Francisco, 13-15 January 2020.
@LocateBio named one of the Top 20 Advanced Therapy biotechs to watch in 2020, curated with input from industry nominations and @Phacilitate. https://www.phacilitate.co.uk/article/top-20-advanced-therapy-biotechs-watch-2020
@LocateBio CEO Nick Staples and CFO/COO John von Benecke will be attending the LSX #Investival and #Jefferies 2019 Healthcare conferences in London on the 19 and 20-21 November respectively. They will be available for partnering and investor meetings.
@LocateBio CEO Nick Staples and CFO John von Benecke are attending #BIOEurope conference in Hamburg, November 11-13 and will be available for partnering and investor meetings
@LocateBio appoints John von Benecke as CFO and COO, and to the Board of Directors. He has raised more than $130m of venture capital to date and taken two start-ups through to successful exit events. http://bit.ly/LocateCFO
@LocateBio will be attending #BioEquity in Barcelona on 20-21 May and #BIO2019 in Philadelphia on 3-6 June. CEO Nick Staples will be available for investor and partnering meetings.
@LocateBio receives £2million of new investment to advance #IntraStem its non-viral gene therapy technology and #TAOS cell delivery platform, and expand its in-house cell and gene therapy pipeline. £1.8million was a direct investment from @MerciaTech and £0.2m from MEIF.